Recently, results from a phase 3 randomized trial (LIBRETTO-531) reported superior progression-free survival with selpercatinib as compared with physician’s choice of either cabozantinib or vandetanib in treatment-naive patients with progressive, advanced RET mutant medullary thyroid cancer; hazard ratio for disease progression or death was 0.28 (95% CI, 0.16–0.48; P < 0.001), and PFS at 12 months was 86.8% (95% CI, 79.8–91.6) in the selpercatinib group and 65.7% (95% CI, 51.9–76.4) in the control group (Hadoux et al. 2023a). Here, RET is linked to medullary thyroid gland carcinoma.